Skip to main content
Clinical Trials/NCT02909114
NCT02909114
Unknown
Phase 2

Phase II Study of Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer

Jing Jin, M.D.1 site in 1 country50 target enrollmentJanuary 2016

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Colorectal Cancer
Sponsor
Jing Jin, M.D.
Enrollment
50
Locations
1
Primary Endpoint
local control assessed by RECIST
Last Updated
9 years ago

Overview

Brief Summary

Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer

Detailed Description

Single arms prospective phase II study of SBRT for oligometastatases from colorectal cancer, the primary concerns are treatment efficacy and toxicities.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
December 2020
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Jing Jin, M.D.
Responsible Party
Sponsor Investigator
Principal Investigator

Jing Jin, M.D.

Medical Doctor

Chinese Academy of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • 18-75 years
  • Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1
  • Diagnosis by pathological examination
  • Primary lesion is under control by surgery
  • Adequate blood counts:
  • White blood cell count ≥3.5 x 109/L
  • Haemoglobin levels ≥100g/L
  • Platelet count ≥100 x 109/L
  • Creatinine levels ≤1.0× upper normal limit (UNL)
  • Urea nitrogen levels ≤1.0× upper normal limit (UNL)

Exclusion Criteria

  • Primary lesion is not under control
  • Pancreatic carcinoma
  • Oligometastases could not be located
  • Pregnancy or breast feeding
  • Symptoms or history of peripheral neuropathy

Outcomes

Primary Outcomes

local control assessed by RECIST

Time Frame: 3 years

Secondary Outcomes

  • >= Grade 3 treatment-related adverse events as assessed by CTCAE v4.0(from radiotherapy start to complete treatment 90 days)
  • overall survival(3 years)

Study Sites (1)

Loading locations...

Similar Trials